Polypurine reverse-Hoogsteen hairpins (PPRHs) are double-stranded DNA molecules formed by two polypurine stretches linked by a pentathymidine loop, with intramolecular reverse-Hoogsteen bonds that allow a hairpin structure. PPRHs bind to polypyrimidine targets by Watson–Crick bonds maintaining simultaneously a hairpin structure due to intramolecular Hoogsteen bonds. Previously, we described the ability of Template-PPRHs to decrease mRNA levels because these PPRHs target the template DNA strand interfering with the transcription process. Now, we designed Coding-PPRHs, a new type of PPRHs that directly target the pre-mRNA. The dihydrofolate reductase (dhfr) gene was selected as a target in breast cancer therapy. These PPRHs caused a high degree of cytotoxicity and a decrease in DHFR mRNA and protein levels, but by a different mechanism of action than Template-PPRHs. Coding-PPRHs interfere with the splicing process by competing with U2 auxiliary factor 65 for binding to the polypyrimidine target sequence, leading to a lower amount of mature mRNA. These new PPRHs showed high specificity as no off-target effects were found. The application of these molecules as therapeutic tools was tested in breast cancer cells resistant to methotrexate, obtaining a noticeable cytotoxicity even though the dhfr locus was amplified. Coding-PPRHs can be considered as new molecules to decrease gene expression at the mRNA level and an alternative to other antisense molecules.
Get full access to this article
View all access options for this article.
References
1.
Aartsma-RusA., van OmmenG.J.2007. Antisense-mediated exon skipping: A versatile tool with therapeutic and research applications. RNA, 13:1609–1624.
2.
AviñóA., FriedenR.M., MoralesJ.C.et al.2002. Properties of triple helices formed by parallel-stranded hairpins containing 8-aminopurines. Nucleic Acids Res., 30:2609–2619.
3.
BeheM.J.1995. An overabundance of long oligopurine tracts occurs in the genome of simple and complex eukaryotes. Nucleic Acids Res., 23:689–695.
4.
BrunoI.G., JinW., CoteG.J.2004. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum. Mol. Genet., 13:2409–2420.
5.
BucherP., YagilG.1991. Occurrence of oligopurine.oligopyrimidine tracts in eukaryotic and prokaryotic genes. DNA Seq., 1:157–72.
ChanP.P., GlazerP.M.1997. Triplex DNA: Fundamentals, advances, and potential applications for gene therapy. J. Mol. Med., 75:267–282.
8.
ChasinL.1985. The dihydrofolate reductase locus. Molecular Cell Genetics. GottesmanM.J. Wiley: New York, 449–488.
9.
CiudadC.J., UrlaubG., ChasinL.A.1988. Deletion analysis of the Chinese hamster dihydrofolate reductase gene promoter. J. Biol. Chem., 263:16274–16282.
10.
ComaS., NoeV., EritjaR., CiudadC.J.2005. Strand displacement of double-stranded DNA by triplex-forming antiparallel purine-hairpins. Oligonucleotides, 15:269–283.
11.
CoolidgeC.J., SeelyR.J., PattonJ.G.1997. Functional analysis of the polypyrimidine tract in pre-mRNA splicing. Nucleic Acids Res., 25:888–896.
12.
CoteJ., DupuisS., WuJ.Y.2001. Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion. J. Biol. Chem., 276:8535–8543.
13.
de AlmagroM.C., ComaS., NoeV., CiudadC.J.2009. Polypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genes. J. Biol. Chem., 284:11579–11589.
14.
DuL., PollardJ.M., GattiR.A.2007. Correction of prototypic ATM splicing mutations and aberrant ATM function with antisense morpholino oligonucleotides. Proc. Natl. Acad. Sci. U.S.A., 104:6007–6012.
GiovannangeliC., HeléneC.1997. Progress in developments of triplex-based strategies. Antisense Nucleic Acid Drug Dev., 7:41–4-21.
17.
IzquierdoJ.M., MajosN., BonnalS.et al.2005. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol. Cell, 19:475–484.
18.
JainA., WangG., VasquezK.M.2008. DNA triple helices: Biological consequences and therapeutic potential. Biochimie, 90:1117–1130.
19.
Le GuinerC., PletA., GalianaD.et al.2001. Polypyrimidine tract-binding protein represses splicing of a fibroblast growth factor receptor-2 gene alternative exon through exon sequences. J. Biol. Chem., 276:43677–43687.
20.
LinC.H., PattonJ.G.1995. Regulation of alternative 3′ splice site selection by constitutive splicing factors. RNA, 1:234–245.
21.
MadsenE.C., MorcosP.A., MendelsohnB.A., GitlinJ.D.2008. In vivo correction of a Menkes disease model using antisense oligonucleotides. Proc. Natl. Acad. Sci. U.S.A., 105:3909–3914.
22.
MarshallN.B., OdaS.K., LondonC.A.et al.2007. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J. Immunol. Methods, 325:114–126.
23.
MaschhoffK.L., PadgettR.A.1992. Phosphorothioate substitution identifies phosphate groups important for pre-mRNA splicing. Nucleic Acids Res., 20:1949–1957.
24.
MichaudS., ReedR.1991. An ATP-independent complex commits pre-mRNA to the mammalian spliceosome assembly pathway. Genes Dev., 5:2534–2546.
25.
NoeV., AlemanyC., ChasinL.A., CiudadC.J.1998. Retinoblastoma protein associates with SP1 and activates the hamster dihydrofolate reductase promoter. Oncogene, 16:1931–1938.
26.
NoeV., AlemanyC., NicolasM., CiudadC.J.2001. Sp1 involvement in the 4beta-phorbol 12-myristate 13-acetate (TPA)-mediated increase in resistance to methotrexate in Chinese hamster ovary cells. Eur. J. Biochem., 268:3163–3173.
27.
PraseuthD., GuieysseA.L., HélèneC.1999. Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochim. Biophys. Acta, 1489:181–206.
28.
RodriguezM., NoeV., AlemanyC.et al.1999. Effects of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells. Int. J. Cancer, 81:785–792.
29.
RyanK., KoolE.T.1998. Triplex-directed self-assembly of an artificial sliding clamp on duplex DNA. Chem. Biol., 5:59–67.
30.
SelgaE., OleagaC., RamírezS.et al.2009. Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med., 1:83.
31.
SenapathyP., ShapiroM.B., HarrisN.L.1990. Splice junctions, branch point sites, and exons: sequence statistics, identification, and applications to genome project. Methods Enzymol., 183:252–278.
32.
ShenH., KanJ.L., GhignaC.et al.2004. A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2. RNA, 10:787–794.
33.
SickmierE.A., FratoK.E., ShenH.et al.2006. Structural basis for polypyrimidine tract recognition by the essential pre-mRNA splicing factor U2AF65. Mol. Cell, 23:49–59.
34.
SinghR., BanerjeeH., GreenM.R.2000. Differential recognition of the polypyrimidine-tract by the general splicing factor U2AF65 and the splicing repressor sex-lethal. RNA, 6:901–911.
35.
SinghR., ValcarcelJ., GreenM.R.1995. Distinct binding specificities and functions of higher eukaryotic polypyrimidine tract-binding proteins. Science, 268:1173–1176.
36.
SternM.Z., GuptaS.K., Salmon-DivonMet al.2009. Multiple roles for polypyrimidine tract binding (PTB) proteins in trypanosome RNA metabolism. RNA, 15:648–665.
37.
SuwanmaneeT., SierakowskaH., FucharoenS., KoleR.2002. Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. Mol. Ther., 6:718–726.
38.
VacekM., SazaniP., KoleR.2003. Antisense-mediated redirection of mRNA splicing. Cell. Mol. Life Sci., 60:825–833.
39.
ValcarcelL.J, SinghR., ZamoreP.D., GreenM.R.1993. The protein Sex-lethal antagonizes the splicing factor U2AF to regulate alternative splicing of transformer pre-mRNA. Nature, 362:171–175.
40.
WoodM., YinH., McCloreyG.2007. Modulating the expression of disease genes with RNA-based therapy. PLoS Genet., 3:e109.
41.
ZamoreP.D., PattonJ.G., GreenM.R.1992. Cloning and domain structure of the mammalian splicing factor U2AF. Nature, 355:609–614.
